You are here: Industry Insights > AstraZeneca

News List

AZ and MSD’s Lynparza shows significant results in ovarian cancer pharmatimes
November 01, 2018
AstraZeneca and MSD’s Lynparza improved progression-free survival by 70% compared to placebo in BRCA-mutated ovarian cancer patients who were in complete or partial response...
AstraZeneca signs $922m licensing deal with Grünenthal pharmaceutical-technology
November 01, 2018
AstraZeneca has announced plans to sell certain prescription medicine rights for Nexium and Vimovo to German pharmaceutical company Grünenthal Group under a $922m deal...
AstraZeneca flogs two drug licenses in $922 million deal pharmafile
November 01, 2018
AstraZeneca has signed a deal with Grünenthal worth up to $922 million in which the latter will acquire the regional rights to two of the pharma giant’s drugs.
AstraZeneca boosts drug discovery through partnership biospectrumasia
October 29, 2018
AstraZeneca boosts drug discovery through partnership
Medicines Discovery Catapult and AstraZeneca collaborate for acoustic mist ionisation mass spectrometry pharmatimes
October 25, 2018
Medicines Discovery Catapult and AstraZeneca have announced they will team up to advance the adoption of Acoustic Mist Ionisation Mass Spectrometry (AMI-MS) within drug discovery.
AstraZeneca to buy 9.8% stake in France’s Innate Pharma expressbpd
October 24, 2018
AstraZeneca will buy the stake via around 6.26 million new shares
AstraZeneca sharpens Imfinzi's lung cancer edge with big survival win fiercepharma
September 28, 2018
AstraZeneca already has an OK to market Imfinzi for stage 3 lung cancer that can't be surgically removed. But just-unveiled survival data will strengthen its case—and its lead over its immuno-oncology rivals
Blueprint’s Tagrisso combination shows early promise in NSCLC fiercebiotech
September 28, 2018
Based on these data, Blueprint is looking into testing the combination in more patients with the same treatment-resistant EGFR-mutant cancer.
AZ grabs EU approval for Imfinzi in advanced lung cancer pharmaphorum
September 27, 2018
The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC pharmatimes
September 27, 2018
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page